Giuseppe Orlando
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giuseppe Orlando has a total of 498 co-authors. Here are the top co-authors by number of shared publications:
Alan C. Farney
Department of Surgery, Section of Transplantation, Winston Salem, USA
21 shared publications- Robert J. Stratta
Department of Surgery, Atrium Health Wake Forest Baptist, Winston-Salem, USA
21 shared publications Amber Reeves‐Daniel
Internal Medicine, Section of Nephrology Wake Forest University School of Medicine Winston‐Salem North Carolina USA
16 shared publicationsJeffrey Rogers
Department of Surgery Section of Transplantation Atrium Health Wake Forest Baptist Winston Salem North Carolina USA
16 shared publications- Andrea Peloso
Hepatology and Transplantation Laboratory, Department of Surgery, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland
14 shared publications Robert J. Stratta
Department of Surgery, Section of Transplantation, Winston Salem, USA
14 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 222, 327-339
Scalable 3D bioprinting of human islets in a pancreatic decellularized extracellular matrix-enriched bioink for beta-cell replacement therapy
- 8 August 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 222, 327-339
Open AccessScalable 3D bioprinting of human islets in a pancreatic decellularized extracellular matrix-enriched bioink for beta-cell replacement therapy
- Open Access
- 12 June 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (6) , e70587
Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report
Introduction: The effects of induction therapy with the anti‐CD52 monoclonal antibody alemtuzumab on age‐specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single‐dose alemtuzumab induction in deceased donor (DD) KT recipients according to different recipient age groups. Methods: Single‐center retrospective nonrandomized cohort review of DDKT recipients stratified by age (30–49/50–69/70 years). All patients received a single 30‐mg intra‐operative dose of alemtuzumab. Standardized management algorithms were used. All patients received triple maintenance immunosuppression with tacrolimus/mycophenolate/steroids. Results: From September 2012 to December 2018, 723 DDKTs were performed with alemtuzumab induction. Donor age (33.1 ± 15.7 vs. 47.3 ± 16.0 vs. 53.3 ± 13.4 years; p < 0.001) and kidney donor profile index (KDPI, 46.5 ± 25.1 vs. 65.5 ± 23.8 vs. 74.4 ± 20.5%; p < 0.001) increased with increasing recipient age groups. Overall patient ( p < 0.001) and graft ( p < 0.001) but not death‐censored graft survival ( p = 0.6) rates decreased with increasing recipient age strata. Rates of delayed graft function, biopsy‐proven acute rejection, and infectious complications at 1‐year post‐transplant were comparable amongst groups. Conclusion: In DDKT recipients, alemtuzumab induction does not appear to confer excess risk of graft failure, acute rejection, or short‐term infectious complications in older patients relative to younger counterparts in the setting of triple maintenance immunosuppression.
- 12 June 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (6) , e70587
Open AccessOutcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report
Introduction: The effects of induction therapy with the anti‐CD52 monoclonal antibody alemtuzumab on age‐specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single‐dose alemtuzumab induction in deceased donor (DD) KT recipients according to different recipient age groups. Methods: Single‐center retrospective nonrandomized cohort review of DDKT recipients stratified by age (30–49/50–69/70 years). All patients received a single 30‐mg intra‐operative dose of alemtuzumab. Standardized management algorithms were used. All patients received triple maintenance immunosuppression with tacrolimus/mycophenolate/steroids. Results: From September 2012 to December 2018, 723 DDKTs were performed with alemtuzumab induction. Donor age (33.1 ± 15.7 vs. 47.3 ± 16.0 vs. 53.3 ± 13.4 years; p < 0.001) and kidney donor profile index (KDPI, 46.5 ± 25.1 vs. 65.5 ± 23.8 vs. 74.4 ± 20.5%; p < 0.001) increased with increasing recipient age groups. Overall patient ( p < 0.001) and graft ( p < 0.001) but not death‐censored graft survival ( p = 0.6) rates decreased with increasing recipient age strata. Rates of delayed graft function, biopsy‐proven acute rejection, and infectious complications at 1‐year post‐transplant were comparable amongst groups. Conclusion: In DDKT recipients, alemtuzumab induction does not appear to confer excess risk of graft failure, acute rejection, or short‐term infectious complications in older patients relative to younger counterparts in the setting of triple maintenance immunosuppression.
- Open Access
- 23 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Extracellular vesicle miR-93-5p cargo regulates glomerular endothelial cell damage in Alport syndrome
Modulation of miRNA expression in glomerular cells is associated with renal disease. Here, we investigated the role of miR-93-5p in mitigating glomerular damage in Alport syndrome and whether the disease-modifying activity of extracellular vesicles from human amniotic fluid stem cells (hAFSC-EVs) is mediated by their miR-93-5p cargo. We identified downregulation of miR-93-5p specifically in glomerular endothelial cells in Alport syndrome along disease progression. Silencing of miR-93-5p in hAFSC-EVs changed the transcriptomic and proteomic profile, regulating EV disease-modifying activity. Compared with naive hAFSC-EVs, silenced hAFSC-EVs did not rescue glomerular endothelial function in vitro and did not restore kidney function in vivo. We established that hAFSC-EVs regulate VEGFR1 and VEGFR2 signaling by miR-93-5p cargo transfer, highlighting that miR-93-5p can restore glomerular endothelial cell biology. Spatial transcriptomics analysis of hAFSC-EV–injected kidneys showed that these EVs can reverse pathways altered during disease progression by stimulating proregenerative processes, specifically in the glomerulus, by regulating miR-93-5p targets. Alteration of glomerular endothelial cell transcriptomics and miR-93-5p targets was also confirmed in biopsies of patients with Alport syndrome using spatial molecular imaging. We demonstrated the critical role of miR-93-5p in glomerular endothelial cells and the capability of hAFSC-EVs to regulate miR-93-5p and its targets in Alport syndrome.
- 23 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Open AccessExtracellular vesicle miR-93-5p cargo regulates glomerular endothelial cell damage in Alport syndrome
Modulation of miRNA expression in glomerular cells is associated with renal disease. Here, we investigated the role of miR-93-5p in mitigating glomerular damage in Alport syndrome and whether the disease-modifying activity of extracellular vesicles from human amniotic fluid stem cells (hAFSC-EVs) is mediated by their miR-93-5p cargo. We identified downregulation of miR-93-5p specifically in glomerular endothelial cells in Alport syndrome along disease progression. Silencing of miR-93-5p in hAFSC-EVs changed the transcriptomic and proteomic profile, regulating EV disease-modifying activity. Compared with naive hAFSC-EVs, silenced hAFSC-EVs did not rescue glomerular endothelial function in vitro and did not restore kidney function in vivo. We established that hAFSC-EVs regulate VEGFR1 and VEGFR2 signaling by miR-93-5p cargo transfer, highlighting that miR-93-5p can restore glomerular endothelial cell biology. Spatial transcriptomics analysis of hAFSC-EV–injected kidneys showed that these EVs can reverse pathways altered during disease progression by stimulating proregenerative processes, specifically in the glomerulus, by regulating miR-93-5p targets. Alteration of glomerular endothelial cell transcriptomics and miR-93-5p targets was also confirmed in biopsies of patients with Alport syndrome using spatial molecular imaging. We demonstrated the critical role of miR-93-5p in glomerular endothelial cells and the capability of hAFSC-EVs to regulate miR-93-5p and its targets in Alport syndrome.
- Open Access
- 5 March 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (3)
Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation
Introduction: The anti‐CD52 monoclonal antibody alemtuzumab is used as an induction agent in kidney transplantation (KT) but remains understudied in septuagenarian recipients. The study purpose was to analyze the safety and efficacy of single‐dose alemtuzumab induction in septuagenarian deceased donor (DD) KT recipients. Methods: Single center retrospective nonrandomized cohort review of septuagenarian DDKT recipients stratified by induction immunosuppression (single dose alemtuzumab versus multi‐dose rabbit anti‐thymocyte globulin [ATG]). Standardized management algorithms were used, and all patients received maintenance immunosuppression with tacrolimus/mycophenolate/steroids. Results: From November 2003 to December 2024, 359 DDKTs were performed in septuagenarian recipients with either alemtuzumab ( n = 270) or ATG induction ( n = 89). Donor and recipient characteristics were largely comparable between the two groups. Five‐year patient (70.3% alemtuzumab versus 82.9% ATG, p = 0.054), graft (60.2% alemtuzumab versus 74.7% ATG, p = 0.04) and death‐censored graft survival (80.0% alemtuzumab versus 89.1% ATG, p = 0.11) rates favored the ATG cohort. Conclusion: ATG induction was associated with improved survival outcomes in our cohort and may be the preferred induction agent in septuagenarians undergoing DDKT versus alemtuzumab. Given the findings of our study, caution is warranted with the use of alemtuzumab in elderly KT patients receiving triple maintenance immunosuppression.
- 5 March 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (3)
Open AccessAlemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation
Introduction: The anti‐CD52 monoclonal antibody alemtuzumab is used as an induction agent in kidney transplantation (KT) but remains understudied in septuagenarian recipients. The study purpose was to analyze the safety and efficacy of single‐dose alemtuzumab induction in septuagenarian deceased donor (DD) KT recipients. Methods: Single center retrospective nonrandomized cohort review of septuagenarian DDKT recipients stratified by induction immunosuppression (single dose alemtuzumab versus multi‐dose rabbit anti‐thymocyte globulin [ATG]). Standardized management algorithms were used, and all patients received maintenance immunosuppression with tacrolimus/mycophenolate/steroids. Results: From November 2003 to December 2024, 359 DDKTs were performed in septuagenarian recipients with either alemtuzumab ( n = 270) or ATG induction ( n = 89). Donor and recipient characteristics were largely comparable between the two groups. Five‐year patient (70.3% alemtuzumab versus 82.9% ATG, p = 0.054), graft (60.2% alemtuzumab versus 74.7% ATG, p = 0.04) and death‐censored graft survival (80.0% alemtuzumab versus 89.1% ATG, p = 0.11) rates favored the ATG cohort. Conclusion: ATG induction was associated with improved survival outcomes in our cohort and may be the preferred induction agent in septuagenarians undergoing DDKT versus alemtuzumab. Given the findings of our study, caution is warranted with the use of alemtuzumab in elderly KT patients receiving triple maintenance immunosuppression.
- Open Access
- 1 March 2026
- Vol. 40 (3) , e70495
Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation.
The anti-CD52 monoclonal antibody alemtuzumab is used as an induction agent in kidney transplantation (KT) but remains understudied in septuagenarian recipients. The study purpose was to analyze the safety and efficacy of single-dose alemtuzumab induction in septuagenarian deceased donor (DD) KT recipients. Single center retrospective nonrandomized cohort review of septuagenarian DDKT recipients stratified by induction immunosuppression (single dose alemtuzumab versus multi-dose rabbit anti-thymocyte globulin [ATG]). Standardized management algorithms were used, and all patients received maintenance immunosuppression with tacrolimus/mycophenolate/steroids. From November 2003 to December 2024, 359 DDKTs were performed in septuagenarian recipients with either alemtuzumab (n = 270) or ATG induction (n = 89). Donor and recipient characteristics were largely comparable between the two groups. Five-year patient (70.3% alemtuzumab versus 82.9% ATG, p = 0.054), graft (60.2% alemtuzumab versus 74.7% ATG, p = 0.04) and death-censored graft survival (80.0% alemtuzumab versus 89.1% ATG, p = 0.11) rates favored the ATG cohort. ATG induction was associated with improved survival outcomes in our cohort and may be the preferred induction agent in septuagenarians undergoing DDKT versus alemtuzumab. Given the findings of our study, caution is warranted with the use of alemtuzumab in elderly KT patients receiving triple maintenance immunosuppression.
- 1 March 2026
- Vol. 40 (3) , e70495
Open AccessAlemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation.
The anti-CD52 monoclonal antibody alemtuzumab is used as an induction agent in kidney transplantation (KT) but remains understudied in septuagenarian recipients. The study purpose was to analyze the safety and efficacy of single-dose alemtuzumab induction in septuagenarian deceased donor (DD) KT recipients. Single center retrospective nonrandomized cohort review of septuagenarian DDKT recipients stratified by induction immunosuppression (single dose alemtuzumab versus multi-dose rabbit anti-thymocyte globulin [ATG]). Standardized management algorithms were used, and all patients received maintenance immunosuppression with tacrolimus/mycophenolate/steroids. From November 2003 to December 2024, 359 DDKTs were performed in septuagenarian recipients with either alemtuzumab (n = 270) or ATG induction (n = 89). Donor and recipient characteristics were largely comparable between the two groups. Five-year patient (70.3% alemtuzumab versus 82.9% ATG, p = 0.054), graft (60.2% alemtuzumab versus 74.7% ATG, p = 0.04) and death-censored graft survival (80.0% alemtuzumab versus 89.1% ATG, p = 0.11) rates favored the ATG cohort. ATG induction was associated with improved survival outcomes in our cohort and may be the preferred induction agent in septuagenarians undergoing DDKT versus alemtuzumab. Given the findings of our study, caution is warranted with the use of alemtuzumab in elderly KT patients receiving triple maintenance immunosuppression.
- 15 October 2025
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 25 (3) , 306-314
From preservation to repair: Mitochondrial transplantation as a paradigm shift in organ transplantation
- 15 October 2025
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 25 (3) , 306-314
From preservation to repair: Mitochondrial transplantation as a paradigm shift in organ transplantation
- 14 July 2025
- Published by Wolters Kluwer Health in Annals of Surgery
Mosaic Loss of Y Chromosome Defines a Proximal Tubular Cell State Associated with Recovery from DGF and of Allograft Quality and Functional Reserve Post DCD Kidney Transplantation
Objective: To determine the drivers of proximal tubular cell regeneration and repair over time in the setting of recovery from delayed graft function (DGF) post donation after cardiac death (DCD) kidney transplantation. Background: DCD Kidney allografts are at increased risk of graft loss. Despite this, due to organ shortages, DCD transplantation is increasing, which offers a novel and valuable platform for the study of adaptive/maladaptive repair mechanisms after injury. Methods: We analyzed the dynamic transcriptional changes in serial biopsies of transplanted DCD kidneys to better understand proximal tubular cell repair and regeneration in DGF at the cellular level. We also quantified loss of Y chromosome in these kidneys to determine the impact of this phenomenon on DGF. Results: One cell state associated with recovery from DGF had a high loss of Y chromosome fraction (29%) compared to pre-transplant healthy proximal tubules (17%) and differentially expressed APOE. A proximal tubule cell state associated with progression to DGF was defined by injury markers VCAM1 and HAVCR1 and proinflammatory and proliferative genes CCL2 and MYC and accounted for over 50% of proximal tubules in time 0 DGF kidney biopsies. Conclusions: Taken together, our dataset of serial biopsies from DCD kidney transplants reveals insights into mechanisms driving injury and repair in the setting of DGF and offers a signature of allograft quality and functional reserve that may optimize allocation at the time of procurement.
- 14 July 2025
- Published by Wolters Kluwer Health in Annals of Surgery
Mosaic Loss of Y Chromosome Defines a Proximal Tubular Cell State Associated with Recovery from DGF and of Allograft Quality and Functional Reserve Post DCD Kidney Transplantation
Objective: To determine the drivers of proximal tubular cell regeneration and repair over time in the setting of recovery from delayed graft function (DGF) post donation after cardiac death (DCD) kidney transplantation. Background: DCD Kidney allografts are at increased risk of graft loss. Despite this, due to organ shortages, DCD transplantation is increasing, which offers a novel and valuable platform for the study of adaptive/maladaptive repair mechanisms after injury. Methods: We analyzed the dynamic transcriptional changes in serial biopsies of transplanted DCD kidneys to better understand proximal tubular cell repair and regeneration in DGF at the cellular level. We also quantified loss of Y chromosome in these kidneys to determine the impact of this phenomenon on DGF. Results: One cell state associated with recovery from DGF had a high loss of Y chromosome fraction (29%) compared to pre-transplant healthy proximal tubules (17%) and differentially expressed APOE. A proximal tubule cell state associated with progression to DGF was defined by injury markers VCAM1 and HAVCR1 and proinflammatory and proliferative genes CCL2 and MYC and accounted for over 50% of proximal tubules in time 0 DGF kidney biopsies. Conclusions: Taken together, our dataset of serial biopsies from DCD kidney transplants reveals insights into mechanisms driving injury and repair in the setting of DGF and offers a signature of allograft quality and functional reserve that may optimize allocation at the time of procurement.
- Open Access
Dose Modeling for Mitochondrial Transplantation in Barrier-Limited Tissues
Mitochondrial transplantation is an emerging regenerative therapy aimed at preventing ischemia– reperfusion injury (IRI) by restoring oxidative metabolism in vulnerable tissues. While early clinical studies have demonstrated feasibility in pediatric myocardium and safety in adult stroke patients, dosing strategies remain undefined for barrier-limited organs where autoregulation, restricted perfusion, and anatomical constraints limit parenchymal uptake. We developed a physiologically grounded computational model to estimate route-specific input dose requirements for brain, spinal cord, and kidney. The model integrates organ-level parameters including tissue mass, regional perfusion or cerebrospinal flow, permeability–surface area product, and extraction efficiency. A benchmark dose of 2 × 10 6 mitochondria per gram, derived from validated cardiac protocols, was applied across delivery scenarios. Sensitivity analysis explored the effects of extraction fraction and tissue mass. Route-adjusted input requirements diverged quantitatively from cardiac-derived estimates, with up to 2-fold increases in central nervous system (CNS) targets and approximately 20% higher dosing required for the kidney. This framework provides a quantitative foundation for translational dose planning in IRI and related conditions.
Open AccessDose Modeling for Mitochondrial Transplantation in Barrier-Limited Tissues
Mitochondrial transplantation is an emerging regenerative therapy aimed at preventing ischemia– reperfusion injury (IRI) by restoring oxidative metabolism in vulnerable tissues. While early clinical studies have demonstrated feasibility in pediatric myocardium and safety in adult stroke patients, dosing strategies remain undefined for barrier-limited organs where autoregulation, restricted perfusion, and anatomical constraints limit parenchymal uptake. We developed a physiologically grounded computational model to estimate route-specific input dose requirements for brain, spinal cord, and kidney. The model integrates organ-level parameters including tissue mass, regional perfusion or cerebrospinal flow, permeability–surface area product, and extraction efficiency. A benchmark dose of 2 × 10 6 mitochondria per gram, derived from validated cardiac protocols, was applied across delivery scenarios. Sensitivity analysis explored the effects of extraction fraction and tissue mass. Route-adjusted input requirements diverged quantitatively from cardiac-derived estimates, with up to 2-fold increases in central nervous system (CNS) targets and approximately 20% higher dosing required for the kidney. This framework provides a quantitative foundation for translational dose planning in IRI and related conditions.
- 3 June 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (6) , e70203
Experience With 117 Donation After Circulatory Death Expanded Criteria Donor Kidney Transplants: What Are the Limits of Acceptability?
Introduction: Nonuse of expanded criteria donor (ECD) kidneys from donation after cardiocirculatory death (DCD) donors remains high. The study purpose was to analyze our experience with kidney transplantation (KT) from DCD donors stratified by ECD versus non‐ECD (standard criteria donor [SCD]). Methods: Single center retrospective cohort study of all primary DCD KT recipients. Results: From April 2003 to January 2024, we performed 671 primary DCD KTs (554 from DCD/SCDs and 117 from DCD/ECDs). Mean donor and recipient ages were 38.3 ± 14.6 DCD/SCD versus 59.4 ± 4.5 years DCD/ECD and 54.0 ± 13.1 DCD/SCD versus 63.0 ± 7.7 years DCD/ECD, respectively (both p < 0.05). Mean Kidney Donor Profile Index (KDPI) values were 53 ± 23% DCD/SCD versus 85 ± 9% DCD/ECD ( p < 0.05). With a mean follow‐up of 71 months DCD/SCD and 58 months DCD/ECD, patient (76.2% DCD/SCD vs. 72.6% DCD/ECD) and graft survival (61.6% DCD/SCD vs. 61.5% DCD/ECD) rates were comparable. Rates of primary nonfunction/thrombosis and delayed graft function were 3.4% for both DCD/SCD and DCD/ECD and 49% DCD/SCD versus 56% DCD/ECD, respectively (both p = NS). The presence of DGF did not influence survival outcomes in DCD/ECD KTs whereas inferior graft survival was noted in DCD/SCD KTs with DGF. However, DGF did have a negative effect on renal function in all groups. DCD/ECD KTs with or without DGF had comparable outcomes to DCD/SCD KTs with DGF. Conclusions: DCD/ECD KTs are associated with inferior functional but similar mid‐term survival outcomes compared to DCD/SCD KTs with DGF. The presence of DGF appears to have a differential effect on survival outcomes in these two groups.
- 3 June 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (6) , e70203
Experience With 117 Donation After Circulatory Death Expanded Criteria Donor Kidney Transplants: What Are the Limits of Acceptability?
Introduction: Nonuse of expanded criteria donor (ECD) kidneys from donation after cardiocirculatory death (DCD) donors remains high. The study purpose was to analyze our experience with kidney transplantation (KT) from DCD donors stratified by ECD versus non‐ECD (standard criteria donor [SCD]). Methods: Single center retrospective cohort study of all primary DCD KT recipients. Results: From April 2003 to January 2024, we performed 671 primary DCD KTs (554 from DCD/SCDs and 117 from DCD/ECDs). Mean donor and recipient ages were 38.3 ± 14.6 DCD/SCD versus 59.4 ± 4.5 years DCD/ECD and 54.0 ± 13.1 DCD/SCD versus 63.0 ± 7.7 years DCD/ECD, respectively (both p < 0.05). Mean Kidney Donor Profile Index (KDPI) values were 53 ± 23% DCD/SCD versus 85 ± 9% DCD/ECD ( p < 0.05). With a mean follow‐up of 71 months DCD/SCD and 58 months DCD/ECD, patient (76.2% DCD/SCD vs. 72.6% DCD/ECD) and graft survival (61.6% DCD/SCD vs. 61.5% DCD/ECD) rates were comparable. Rates of primary nonfunction/thrombosis and delayed graft function were 3.4% for both DCD/SCD and DCD/ECD and 49% DCD/SCD versus 56% DCD/ECD, respectively (both p = NS). The presence of DGF did not influence survival outcomes in DCD/ECD KTs whereas inferior graft survival was noted in DCD/SCD KTs with DGF. However, DGF did have a negative effect on renal function in all groups. DCD/ECD KTs with or without DGF had comparable outcomes to DCD/SCD KTs with DGF. Conclusions: DCD/ECD KTs are associated with inferior functional but similar mid‐term survival outcomes compared to DCD/SCD KTs with DGF. The presence of DGF appears to have a differential effect on survival outcomes in these two groups.
- 10 March 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (3) , e70131
Safety and Efficacy of Belatacept in Pancreas Transplantation: A Case Series
- 10 March 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (3) , e70131
Safety and Efficacy of Belatacept in Pancreas Transplantation: A Case Series